SCHEMBL13826445

SCHEMBL13826445

COCCOC(=O)Cc1ccc(N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
GAA P10253 2/20 0.48
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
YWHAG P61981 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.43
TSHR P16473 2/20 0.43
CYP19A1 P11511 1/20 0.43
GFER P55789 1/20 0.41
ALOX5 P09917 1/20 0.41
MAPK1 P28482 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KLK7 P49862 1/20 0.40
PPIB P23284 1/20 0.40
PPIA P62937 1/20 0.40
PPID Q08752 1/20 0.40
PPIG Q13427 1/20 0.40
POLB P06746 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30704448 0.95 ALDH1A1 (0.44) ALDH1A1GAACYP4F2CYP4A11YWHAG
SCHEMBL10175300 0.84 ALDH1A1 (0.49) ALDH1A1GAACYP4F2CYP4A11YWHAG
SCHEMBL6354463 0.84 YWHAG (0.50) ALDH1A1GAACYP4F2CYP4A11YWHAG
SCHEMBL11038201 0.84 CYP1A2 (0.47) ALDH1A1GAAYWHAGL3MBTL1TSHR
SCHEMBL19336121 0.83 ALDH1A1 (0.48) ALDH1A1GAACYP4F2CYP4A11YWHAG
SCHEMBL16661855 0.83 ALDH1A1 (0.68) ALDH1A1GAAL3MBTL1KLK7POLB
SCHEMBL9736831 0.82 ALDH1A1 (0.61) ALDH1A1L3MBTL1TSHRALOX5MAPK1
SCHEMBL10899541 0.81 CYP1A2 (0.61) ALDH1A1GAAL3MBTL1TSHRNPC1
SCHEMBL18373632 0.81 THRB (0.44) ALDH1A1GAACYP4F2CYP4A11YWHAG
Ammonia Solution, Strong SCHEMBL27732594 0.81 ALDH1A1 (0.59) ALDH1A1GAAL3MBTL1TSHRALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073905-B2 Rock inhibitors AMAKEM NV (BE) 2015-07-07 US disclosed
US-9073905-B2 Rock inhibitors AMAKEM NV (BE) 2015-07-07 US disclosed
US-20140057942-A1 NOVEL ROCK INHIBITORS AMAKEM NV (BE) 2014-02-27 US disclosed
US-20140057942-A1 NOVEL ROCK INHIBITORS AMAKEM NV (BE) 2014-02-27 US disclosed
WO-2012146724-A2 NOVEL ROCK INHIBITORS AMAKEM NV (BE) 2012-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057942-A1 NOVEL ROCK INHIBITORS ROCK1, ROCK2, CIT ALDH1A1 3011/4885GAA 4282/4885CYP4F2 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.